Association of HMG-CoA reductase inhibitors with neuropathy

Ann Pharmacother. 2003 Feb;37(2):274-8. doi: 10.1177/106002800303700220.

Abstract

Objective: To review the possible association between statins and peripheral neuropathy.

Data sources: Literature was obtained from MEDLINE (1984-September 2002) and International Pharmaceutical Abstracts (1970-June 2002). Key search terms included statin, neuropathy, and HMG-CoA reductase inhibitor.

Data synthesis: Epidemiologic studies and case reports suggest an increased risk of peripheral neuropathy with statin drugs. Most patients were receiving long-term therapy, although the onset was highly variable. The majority of cases were at least partially reversible with drug cessation. Specific risk factors or mechanisms have not been identified.

Conclusions: Observational data suggest a link between chronic statin use and increased risk of peripheral neuropathy. However, the risk appears to be small relative to the significant cardioprotective benefits.

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
  • Male
  • Middle Aged
  • Peripheral Nervous System Diseases / chemically induced*
  • Risk Factors
  • Time Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors